Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Active Biotech Initiates Phase-II Clinical Trial For Prostate Cancer Drug
Active Biotech has announced that patient enrollment to the phase II clinical trial for TASQ, a novel compound for the treatment of prostate cancer, is completed. The company
Active Biotech has announced that patient enrollment to the phase II clinical trial for TASQ, a novel compound for the treatment of prostate cancer, is completed. The company
Rexahn has announced that it has completed its registered direct offering of common stock and warrants. Rodman & Renshaw acted as the exclusive placement agent for this transaction.
Merz Pharmaceuticals has announced results from two randomized, active controlled clinical trials in patients with blepharospasm and cervical dystonia. The results were presented at the Movement Disorder Society
Alnylam and Cubist have reported preliminary data from their Phase II study of Aln-Rsv01, an RNAi therapeutic in development for the treatment of respiratory syncytial virus (RSV) infection.
Seattle Genetics has reported data from a phase-I clinical trial of SGN-35 administered to patients with Hodgkin lymphoma and other CD30-positive hematologic malignancies. Data highlights include longer median
Seattle Genetics has reported multiple objective responses at well-tolerated doses from a phase-I clinical trial of lintuzumab (SGN-33) in patients with acute myeloid leukemia (AML). Lintuzumab is a
Merck has presented new data at the American Diabetes Association (ADA’) 69th Annual Scientific Sessions. It showed that initial treatment with JANUMET (sitagliptin/metformin) provided greater blood sugar improvements
Micromet has announced that the German Multicenter ALL Study Group (GMALL) presented phase-II clinical data of the BiTE antibody blinatumomab (MT103) at the 14th Congress of the European
MDRNA has announced in-vivo data from a bladder cancer model demonstrating effective localized delivery of a UsiRNA to a solid tumor, thus further expanding the delivery capabilities of
Progenics has announced the discontinuation of the development program for PRO 206, a pre-clinical compound for the treatment of hepatitis-C virus (HCV) infection. The decision was made as